Summary

Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are the clinical gold standards for screening blood sugar levels, yet they provide only static snapshots that fail to reflect the highly dynamic and heterogeneous nature of metabolic impairment. However, continuous glucose monitoring (CGM) is reshaping our understanding of these levels. While the medical community already has begun capitalizing on CGM for diabetes management, a new study has the potential to change current clinical practices for cardiovascular disease risk stratification in individuals without diabetes.

AI summaries can be wrong sometimes—always verify important details using the source article.